Second Patent Cliff Lies Ahead for Pharma With $251 Billion in Sales at Risk by 2024

Second Patent Cliff Lies Ahead for Pharma With $251 Billion in Sales at Risk by 2024

Source: 
Center for Biosimilars
snippet: 

EvaluatePharma, a company that provides consensus forecasts of the pharmaceutical and biotechnology sphere, recently published the 11th edition of its World Preview. In this 2018 installment, the company provided an overview of what investors and other stakeholders can expect to see in the industry from 2018 to 2024.